The Latest Cardiac and Vascular News
Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance commercial readiness activities in support of an anticipated Q4 2022 launch of FUROSCIX, if approved Ended Q2 with cash, cash equivalents, restricted cash and investments of $56.0 million […]
MINNEAPOLIS, Aug. 09, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022, which included the following highlights: Generated $2.2 million in total revenue for the second quarter 2022, up 15% sequentially from the first quarter of 2022, Enrolled first […]
– Generated 47.8% growth in CGuard™ revenue year-over-year – – Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission – – Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company – — Management to Host Investor Conference […]
REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardiology: Basic to Translational Science CAMBRIDGE, Mass.–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused […]
Getz adds 25 Years of Financial and Healthcare Leadership to Growing Company SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced the addition of Heather C. Getz, CPA, MBA, to its Board of Directors. Getz brings more than 25 years of corporate experience […]
SUWANEE, GA, Aug. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – SANUWAVE Health, Inc. (OTCPK: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the closing of its $12 million private placement. Use of proceeds is to expand production capacity to meet demand, pay off an existing debt facility, […]
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Completed enrollment in the HALO Phase 2 trial for baxdrostat in patients with uncontrolled hypertension with 249 patients randomized; topline data expected in the second half […]
SUWANEE, GA, Aug. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – SANUWAVE Health, Inc. (OTCPK: SNWV), a leading provider of next-generation wound care products, is pleased to announce the appointment of Mr. Morgan C. Frank as new Board Chairman effective today, August 5, 2022. Mr. Frank has been a principal at the life […]
ATLANTA, Aug. 4, 2022 /PRNewswire/ — Second Quarter and Recent Business Highlights: Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second quarter of 2021, an increase of 6% on a GAAP basis and 9% on a non-GAAP constant currency basis Enrolled first patients in U.S. AMDS clinical trial, PERSEVERE […]
Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass., Aug. 4, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the second quarter ended June 30, 2022. “The […]
